stockrowAbbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- +28.9%
- Total debt
- +142.7%
Quarter to September 2026, against a year earlier
Follow ABT
Alert me
Abbott Laboratories (ABT) EBITDA
Abbott Laboratories's EBITDA for fiscal 2025 was $11.2B, up 11.2% from $10.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was $10.8B. Over the past ten years it has ranged from $4.3B (fiscal 2015) to $12.0B (fiscal 2021); the current reading is higher than 82% of that period. Abbott Laboratories ranks 1st of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $11.2B | 11.21% |
| FY2024 | $10.0B | 3.31% |
| FY2023 | $9.7B | (16.41%) |
| FY2022 | $11.6B | (2.79%) |
| FY2021 | $12.0B | 37.76% |
| FY2020 | $8.7B | 15.08% |
| FY2019 | $7.5B | 8.42% |
| FY2018 | $7.0B | 26.61% |
| FY2017 | $5.5B | 20.97% |
| FY2016 | $4.5B | 4.72% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $2.8B | 28.17% |
| Mar 2026 | $2.1B | (29.41%) |
| Dec 2025 | $3.0B | 6.85% |
| Sep 2025 | $2.8B | 0.67% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ABT Abbott Laboratories | $10.8B |
| MDT Medtronic PLC compare | $9.7B |
| SYK Stryker Corporation compare | $6.6B |
| BSX Boston Scientific Corporation compare | $5.4B |
| GEHC GE HealthCare Technologies Inc. compare | $3.5B |
| PHG Koninklijke Philips N.V. compare | $3.1B |
| STE STERIS plc compare | $1.7B |
| EW Edwards Lifesciences Corporation compare | $1.6B |
| DXCM DexCom, Inc. compare | $1.5B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ABT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement